Flagship Pioneering Special Opportunities Fund Ii, L.p. - Net Worth and Insider Trading

Flagship Pioneering Special Opportunities Fund Ii, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Flagship Pioneering Special Opportunities Fund Ii, L.p. owns 3 companies in total, including Foghorn Therapeutics Inc (FHTX) , Sigilon Therapeutics Inc (SGTX) , and Omega Therapeutics Inc (OMGA) .

Click here to see the complete history of Flagship Pioneering Special Opportunities Fund Ii, L.p.’s form 4 insider trades.

Insider Ownership Summary of Flagship Pioneering Special Opportunities Fund Ii, L.p.

Ticker	Comapny	Transaction Date	Type of Owner
FHTX	Foghorn Therapeutics Inc	2020-10-22	10 percent owner
SGTX	Sigilon Therapeutics Inc	2020-12-03	10 percent owner
OMGA	Omega Therapeutics Inc	2021-07-29	10 percent owner

Flagship Pioneering Special Opportunities Fund Ii, L.p. Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Flagship Pioneering Special Opportunities Fund Ii, L.p. Ownership Network

Ownership Network List of Flagship Pioneering Special Opportunities Fund Ii, L.p.

No Data

Ownership Network Relation of Flagship Pioneering Special Opportunities Fund Ii, L.p.

Flagship Pioneering Special Opportunities Fund Ii, L.p. Owned Company Details

What does Foghorn Therapeutics Inc do?

Who are the key executives at Foghorn Therapeutics Inc?

Flagship Pioneering Special Opportunities Fund Ii, L.p. is the 10 percent owner of Foghorn Therapeutics Inc. Other key executives at Foghorn Therapeutics Inc include Chief People Officer Carlos Costa , See Remarks Steven F. Bellon , and Chief Strategy/Bus Ops Officer Fanny Cavalie .

Foghorn Therapeutics Inc (FHTX) Insider Trades Summary

Over the past 18 months, Flagship Pioneering Special Opportunities Fund Ii, L.p. made no insider transaction in Foghorn Therapeutics Inc (FHTX). Other recent insider transactions involving Foghorn Therapeutics Inc (FHTX) include a net sale of 58,859 shares made by Carlos Costa , a net sale of 311,297 shares made by Samuel Agresta , and a net sale of 20,000 shares made by Steven F. Bellon .

In summary, during the past 3 months, insiders sold 78,859 shares of Foghorn Therapeutics Inc (FHTX) in total and bought 0 shares, with a net sale of 78,859 shares. During the past 18 months, 401,156 shares of Foghorn Therapeutics Inc (FHTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 401,156 shares.

Foghorn Therapeutics Inc (FHTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Foghorn Therapeutics Inc Insider Transactions

No Available Data

What does Sigilon Therapeutics Inc do?

Who are the key executives at Sigilon Therapeutics Inc?

Flagship Pioneering Special Opportunities Fund Ii, L.p. is the 10 percent owner of Sigilon Therapeutics Inc. Other key executives at Sigilon Therapeutics Inc include 10 percent owner Lilly Eli & Co , 10 percent owner Shenandoah Acquisition Corp , and CHIEF OF STAFF AND CLO Matthew Paul Kowalsky .

Sigilon Therapeutics Inc (SGTX) Insider Trades Summary

Over the past 18 months, Flagship Pioneering Special Opportunities Fund Ii, L.p. made no insider transaction in Sigilon Therapeutics Inc (SGTX). Other recent insider transactions involving Sigilon Therapeutics Inc (SGTX) include a net purchase of 1,718,493 shares made by Lilly Eli & Co ,

In summary, during the past 3 months, insiders sold 0 shares of Sigilon Therapeutics Inc (SGTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sigilon Therapeutics Inc (SGTX) were sold and 1,718,493 shares were bought by its insiders, resulting in a net purchase of 1,718,493 shares.

Sigilon Therapeutics Inc (SGTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sigilon Therapeutics Inc Insider Transactions

No Available Data

What does Omega Therapeutics Inc do?

Who are the key executives at Omega Therapeutics Inc?

Flagship Pioneering Special Opportunities Fund Ii, L.p. is the 10 percent owner of Omega Therapeutics Inc. Other key executives at Omega Therapeutics Inc include director & 10 percent owner Richard A Young , 10 percent owner Flagship Pioneering Fund Vii General Partner Llc , and 10 percent owner Flagship Pioneering Fund Vii, L.p. .

Omega Therapeutics Inc (OMGA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Omega Therapeutics Inc (OMGA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Omega Therapeutics Inc (OMGA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Omega Therapeutics Inc (OMGA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Omega Therapeutics Inc Insider Transactions

No Available Data

Flagship Pioneering Special Opportunities Fund Ii, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Flagship Pioneering Special Opportunities Fund Ii, L.p.. You might contact Flagship Pioneering Special Opportunities Fund Ii, L.p. via mailing address: 55 Cambridge Parkway, Cambridge Ma 02142.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.